Statistik Asas
| LEI | 549300NLVVVRGBF0WG69 |
| CIK | 1347242 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lipella Pharmaceuticals Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella P |
|
| June 25, 2025 |
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting Exhibit 99.2 Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting PITTSBURGH, PA – June 25, 2025 – Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stock |
|
| June 25, 2025 |
LIPELLA PHARMACEUTICALS INC. LETTER FROM THE CEO Exhibit 99.1 LIPELLA PHARMACEUTICALS INC. LETTER FROM THE CEO Dear Fellow Stockholders: Over the past few days, I have received many calls, texts, and emails asking questions about our status. In a genuine effort to keep stockholders up to date, I have reproduced the majority of questions received, along with responses so that all stockholders can understand where the Company currently stands and |
|
| June 25, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commiss |
|
| June 20, 2025 |
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market Exhibit 99.1 Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market PITTSBURGH, PA – June 20, 2025 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company’s common stock from The Na |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commiss |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commiss |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2025 (May 12, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorpora |
|
| May 15, 2025 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commissi |
|
| May 15, 2025 |
Exhibit 99.1 Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” o |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commis |
|
| April 9, 2025 |
Exhibit 3.1 Page 1 Delaware The First State I, CHARUNI PATIBANDA-SANCHEZ, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF “LIPELLA PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE EIGHTH DAY OF APRIL, A.D. 2025, AT 2:30 O`CLOCK P.M. 1 LIPELLA PHAR1VIACEUTICALS INC. CERTIFICATE OF AMENDMENT OF CERTIFICATE OF |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 (April 8, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorpo |
|
| April 7, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 (April 4, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorpo |
|
| April 7, 2025 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT April 4, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Lipella Pharmaceuticals Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| April 4, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333–286199 PROSPECTUS Up to 4,921,483 Shares of Common Stock Issuable Upon Conversion of Shares of Series B Preferred Stock Up to 536,959 Shares of Common Stock Issuable Upon Conversion of Shares of Series C Preferred Stock Up to 158,817 Shares of Common Stock Issuable Upon Exercise of Placement Agent Warrants Lipella Pharmaceuticals Inc. This pros |
|
| April 4, 2025 |
LIPELLA PHARMACEUTICALS INC. Up to $2,641,881 of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-276815 Prospectus Supplement (To Prospectus dated February 8, 2024) LIPELLA PHARMACEUTICALS INC. Up to $2,641,881 of Common Stock We have entered into an At the Market Offering Agreement dated as of April 4, 2025 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale of shares |
|
| April 1, 2025 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 April 1, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington D.C. 20549 RE: Lipella Pharmaceuticals Inc. File No. 333-286199 Registration Statement on Form S-3 Ladies and Gentlemen: In accordance with Rule 461 under t |
|
| March 28, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2025 As filed with the U.S. Securities and Exchange Commission on March 27, 2025 Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other jurisdiction of incorporation or organization |
|
| March 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lipella Pharmaceuticals Inc. |
|
| March 28, 2025 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Lipella Pharmaceuticals Inc. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share (our “Common Stock”). G |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41575 Lipella Pharmaceuticals Inc. |
|
| March 28, 2025 |
Exhibit 97.1 LIPELLA PHARMACEUTICALS INC. (the “Company”) CLAWBACK POLICY Effective as of December 1, 2023 Background The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philoso |
|
| March 18, 2025 |
Consulting and Advisory Agreement, dated March 17, 2025, by and between the Company and Spartan. Exhibit 10.5 CONSULTING AGREEMENT AND ADVISORY AGREEMENT This Consulting Agreement (the “Agreement”) is made as of March 17, 2025, between Spartan Capital Securities, LLC (the “Consultant” or “Advisor”), and Lipella Pharmaceuticals Inc. (the “Company”). The Company and the Consultant are collectively herein referred to as the “Parties.” WITNESSETH WHEREAS, the Consultant is a broker-dealer, licens |
|
| March 18, 2025 |
Exhibit 10.6 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), effective as of March 17, 2025 (the “Consulting Agreement”), the Corporation is obligated to issue to S |
|
| March 18, 2025 |
Exhibit 10.9 LIPELLA PHARMACEUTICALS INC. and Nevada Agency and Transfer Company, as Warrant Agent Warrant Agency Agreement WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, effective as of March 17, 2025 (“Agreement”), between Lipella Pharmaceuticals Inc., a corporation organized under the laws of the State of Delaware (the “Company”), and Nevada Agency and Transfer Company, a corporation organi |
|
| March 18, 2025 |
Exhibit 10.1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placemen |
|
| March 18, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 18, 2025 |
Form of March Offering Registration Rights Agreement. Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of , 2025 by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the undersigned signatory hereto (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 (March 12, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| March 18, 2025 |
Placement Agent Agreement, effective March 17, 2025, by and between the Company and Spartan. Exhibit 10.4 PLACEMENT AGENT AGREEMENT March 17, 2025 Spartan Capital Securities, LLC 45 Broadway New York, New York 10006 Re: Placement Agent Agreement Gentlemen: This letter (this “Agreement”) is in confirmation of our agreement with you pertaining to the private offering (the “Offering”) coordinated by Spartan Capital Securities, LLC (the “Placement Agent,” “Spartan” or “you”) as exclusive plac |
|
| March 18, 2025 |
Exhibit 10.7 SUBSCRIPTION FOR WARRANTS EXERCISABLE FOR shares of Series B Non-Voting Convertible Preferred Stock of Lipella Pharmaceuticals Inc. (the “Company”) 1. On the Signature Page for the Subscription Agreement, Date and Fill in the number of shares of the Company’s Series B non-voting convertible preferred stock, par value $0.0001 per share (the “Preferred Stock”), underlying the Company’s |
|
| March 11, 2025 |
Irrevocable Proxy and Power of Attorney. Exhibit 10.1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placemen |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 (March 5, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorp |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 (February 25, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of inc |
|
| March 3, 2025 |
Exhibit 10.4 SECOND AMENDMENT TO CONSULTING AGREEMENT AND ADVISORY AGREEMENT This Second Amendment (the “Amendment”) to the Consulting Agreement and Advisory Agreement, by and between Lipella Pharmaceuticals Inc. (the “Company”) and Spartan Capital Securities, LLC (the “Consultant”), is made as of February 28, 2025. Capitalized terms used but not defined herein shall have the meanings ascribed to |
|
| March 3, 2025 |
Irrevocable Proxy and Power of Attorney. Exhibit 10.1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placemen |
|
| February 24, 2025 |
Exhibit 10.1 SECOND AMENDMENT TO PLACEMENT AGENT AGREEMENT This Second Amendment to Placement Agent Agreement (the “Amendment”) is made as of February 23, 2025, by and between Lipella Pharmaceuticals Inc. (the “Company”) and Spartan Capital Securities, LLC (the “Placement Agent”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Placement Agent Agreemen |
|
| February 24, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 (February 23, 2025) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of |
|
| February 11, 2025 |
Exhibit 99.2 Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dos |
|
| February 11, 2025 |
Exhibit 99.1 Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administrat |
|
| February 11, 2025 |
Exhibit 99.3 |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Com |
|
| January 16, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284172 PROSPECTUS Up to 972,151 Shares of Common Stock Issuable Upon Conversion of Shares of Series B Preferred Stock Up to 303,041 Shares of Common Stock Issuable Upon Conversion of Shares of Series C Preferred Stock Up to 97,216 Shares of Common Stock Issuable Upon Exercise of Placement Agent Warrants Lipella Pharmaceuticals Inc. This prospec |
|
| January 13, 2025 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 January 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington D.C. 20549 RE: Lipella Pharmaceuticals Inc. File No. 333-284172 Registration Statement on Form S-3 Ladies and Gentlemen: In accord |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| January 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lipella Pharmaceuticals Inc. |
|
| January 7, 2025 |
As filed with the U.S. Securities and Exchange Commission on January 7, 2025 As filed with the U.S. Securities and Exchange Commission on January 7, 2025 Registration No. 333– UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other jurisdiction of incorporation or organizatio |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Com |
|
| January 6, 2025 |
Irrevocable Proxy and Power of Attorney. Exhibit 10.1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placemen |
|
| January 3, 2025 |
Irrevocable Proxy and Power of Attorney Exhibit 1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc. |
|
| December 30, 2024 |
Exhibit 3.1(i)(a) Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “LIPELLA PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE ELEVENTH DAY OF DECEMBER, A.D. 2024, AT 5:36 O’CLOCK P.M. 3925021 8100 SR# 20244465629 /s/ Jeffrey W. Bullock Jeffrey W. Bulloc |
|
| December 30, 2024 |
Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS DOCUMENT NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 (December 20, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of |
|
| December 30, 2024 |
Exhibit 3.1(i)(c) Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “LIPELLA PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE TWENTY-THIRD DAY OF DECEMBER, A.D. 2024, AT 4:20 O’CLOCK P.M. 3925021 8100 SR# 20244591410 /s/ Jeffrey W. Bullock Jeffrey W. Bu |
|
| December 30, 2024 |
Exhibit 10.2 SUBSCRIPTION FOR shares of Series B Non-Voting Convertible Preferred Stock of Lipella Pharmaceuticals Inc. (the “Company”) 1. On the Signature Page for the Subscription Agreement, Date and Fill in the number of shares of the Company’s Series B non-voting convertible preferred stock, par value $0.0001 per share (the “Preferred Stock”), that you wish to purchase at a price of $100.00 pe |
|
| December 30, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [ ], 2024 by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and the undersigned signatory hereto (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in |
|
| December 30, 2024 |
Irrevocable Proxy and Power of Attorney. Exhibit 10.1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Corporation”), and Spartan Capital Securities, LLC, including any designee thereof (“Spartan”), dated as of December 5, 2024, as amended by that certain Amendment to Consulting Agreement and Placemen |
|
| December 30, 2024 |
Exhibit 3.1(i)(b) Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF CORRECTION OF “LIPELLA PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE TWENTIETH DAY OF DECEMBER, A.D. 2024, AT 4:47 O’CLOCK P.M. 3925021 8100 SR# 20244574396 /s/ Jeffrey W. Bullock Jeffrey W. Bulloc |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Com |
|
| December 27, 2024 |
Irrevocable Proxy and Power of Attorney Exhibit 1 Irrevocable Proxy and Power of Attorney Pursuant to that certain (i) consulting agreement and advisory agreement, by and between Lipella Pharmaceuticals Inc. |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Com |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| December 10, 2024 |
Exhibit 10.1 PLACEMENT AGENT AGREEMENT December 5, 2024 Spartan Capital Securities, LLC 45 Broadway New York, New York 10006 Re: Placement Agent Agreement Gentlemen: This letter (this “Agreement”) is in confirmation of our agreement with you pertaining to the private offering (the “Offering”), coordinated by Spartan Capital Securities, LLC (the “Placement Agent,” “Spartan” or “you”) as exclusive p |
|
| December 10, 2024 |
Exhibit 10.2 CONSULTING AGREEMENT AND ADVISORY AGREEMENT This Consulting Agreement (the “Agreement”) is made as of December 5, 2024, between Spartan Capital Securities, LLC (the “Consultant” or “Advisor”), and Lipella Pharmaceuticals Inc. (the “Company”). The Company and the Consultant are collectively herein referred to as the “Parties.” WITNESSETH WHEREAS, the Consultant is a broker-dealer, lice |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| December 10, 2024 |
Exhibit 10.3 AMENDMENT TO CONSULTING AGREEMENT AND PLACEMENT AGENCY AGREEMENT This Amendment (the “Amendment”) is made as of December 10, 2024, by and between Lipella Pharmaceuticals Inc. (the “Company”) and Spartan Capital Securities, LLC (the “Consultant” and “Placement Agent”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Consulting Agreement (de |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| November 14, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Huang Leaf - SC 13G/A Passive Investment SC 13G/A 1 g084546sch13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L209 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check th |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipe |
|
| November 14, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Gruber Michele - SC 13G/A Passive Investment SC 13G/A 1 g084548sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L209 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| November 7, 2024 |
Certificate of Amendment to Certificate of Incorporation of Lipella Pharmaceuticals Inc. Exhibit 3.1(i) |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| November 1, 2024 |
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split Exhibit 99.1 Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split PITTSBURGH, PA – November 1, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its commo |
|
| November 1, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| October 18, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 (October 16, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of i |
|
| October 17, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Kaufman Jonathan H - SC 13D/A Activist Investment SC 13D/A 1 g084491sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd F |
|
| October 17, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Chancellor Michael B - SC 13D/A Activist Investment SC 13D/A 1 g084490sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1251 Avenue of the Ame |
|
| September 11, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 (September 10, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction |
|
| August 23, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 (August 21, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of inc |
|
| August 19, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Chancellor Michael B - SC 13D/A Activist Investment SC 13D/A 1 g084401sch13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1251 Avenue of the Am |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella P |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2024 |
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT lipella pharmaceuticals inc. Warrant Shares: Initial Exercise Date: August , 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after th |
|
| August 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 31, 2024, between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| August 1, 2024 |
Exhibit 99.2 Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 (PRNEWSWIRE) – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has c |
|
| August 1, 2024 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-276815 Prospectus Supplement (To Prospectus dated February 8, 2024) LIPELLA PHARMACEUTICALS INC. 399,000 Shares of Common Stock Pre-Funded Warrants to purchase up to 1,667,000 Shares of Common Stock Up to 1,667,000 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 399,000 shares of our common stock, par value $ |
|
| August 1, 2024 |
Exhibit 99.1 Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 (PRNEWSWIRE) – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 (July 31, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorp |
|
| August 1, 2024 |
Exhibit 10.2 July 31, 2024 STRICTLY CONFIDENTIAL Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 Attn: Jonathan Kaufman, President and Chief Executive Officer Dear Dr. Kaufman: This letter agreement (this “Agreement”) constitutes the agreement between Lipella Pharmaceuticals Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall |
|
| August 1, 2024 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| May 9, 2024 |
Suite 504 Lease Agreement, by and between the Company and Bridgeway, effective January 1, 2024 Exhibit 10.1 LEASE AGREEMENT PART I - BASIC LEASE INFORMATION This Lease Agreement (“Lease”) is made and executed this 28th day of December 2023, by and between Bridgeway Development Corporation (“Landlord”) and Lipella Pharmaceuticals Inc. (“Tenant”). This Lease consists of the following two parts: Part I which sets forth terms defined in this Lease (and certain obligations under the Lease) and w |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella |
|
| May 6, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Kaufman Jonathan H - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| April 19, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 (April 17, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 (April 11, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| April 12, 2024 |
Series A Elimination Certificate. Exhibit 3.1 IN WITNESS WHEREOF, this Elimination of Certificate of Designation of the Preferences, Rights and Limitations of Series A Preferred Stock of Lipella Pharmaceuticals Inc. has been executed by a duly authorized officer of the Company on this 10th day of April, 2024. /s/ Jonathan Kaufman Jonathan Kaufman Chief Executive Officer |
|
| March 19, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Kaufman Jonathan H - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| March 15, 2024 |
Exhibit 10.2 AFFILIATE STOCK PURCHASE AGREEMENT This Affiliate Stock Purchase Agreement (this “Agreement”), is made as of March 13, 2024, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Michael Chancellor (the “Purchaser”). RECITALS WHEREAS, the Purchaser wishes to purchase, and the Company wishes to sell to the Purchaser, the equivalent of $100,000 worth o |
|
| March 15, 2024 |
Lipella Pharmaceuticals Inc. 2020 Stock Incentive Plan, as amended and restated (filed herewith). Exhibit 4.4 LIPELLA PHARMACEUTICALS INC. AMENDED AND RESTATED 2020 STOCK INCENTIVE PLAN 1. PURPOSE The purpose of this Amended and Restated 2020 Stock Incentive Plan (the “Plan”) is to encourage key employees, directors, and consultants of Lipella Pharmaceuticals Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by providing favorable oppor |
|
| March 15, 2024 |
As filed with Securities and Exchange Commission on March 15, 2024 As filed with Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 15, 2024 |
Exhibit 1 AFFILIATE STOCK PURCHASE AGREEMENT This Affiliate Stock Purchase Agreement (this “Agreement”), is made as of March 13, 2024, by and between Lipella Pharmaceuticals Inc. |
|
| March 15, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Chancellor Michael B - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| March 15, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Kaufman Jonathan H - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| March 15, 2024 |
EX-1 2 g084123ex1.htm EXHIBIT 1 Exhibit 1 AFFILIATE STOCK PURCHASE AGREEMENT This Affiliate Stock Purchase Agreement (this “Agreement”), is made as of March 13, 2024, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Michael Chancellor (the “Purchaser”). RECITALS WHEREAS, the Purchaser wishes to purchase, and the Company wishes to sell to the Purchaser, the e |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 (March 13, 2024) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| March 15, 2024 |
Exhibit 10.1 AFFILIATE STOCK PURCHASE AGREEMENT This Affiliate Stock Purchase Agreement (this “Agreement”), is made as of March 13, 2024, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Jonathan Kaufman (the “Purchaser”). RECITALS WHEREAS, the Purchaser wishes to purchase, and the Company wishes to sell to the Purchaser, the equivalent of $100,000 worth of |
|
| March 15, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Lipella Pharmaceuticals Inc. |
|
| March 6, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Chancellor Michael B - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| March 6, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Kaufman Jonathan H - SC 13D/A Activist Investment SC 13D/A 1 g084099sc13d.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Fl |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41575 Lipella Pharmaceuticals Inc. |
|
| February 27, 2024 |
Exhibit 14.1 LIPELLA PHARMACEUTICALS INC. Code of Conduct and Ethics For Associates, Officers and Directors 1. Introduction This Code of Conduct and Ethics (the “Code”), as adopted by the Board of Directors (the “Board”) and administered through the Audit Committee (the “Committee”), sets forth requirements to be followed by Lipella Pharmaceuticals Inc. and its subsidiaries (individually and colle |
|
| February 27, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266397 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus Dated December 19, 2022 1,759,957 SHARES OF COMMON STOCK This prospectus supplement amends and supplements the prospectus dated December 19, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of the Registration Statement on Form S-1, as amended (No. 333-266 |
|
| February 27, 2024 |
Insider trading policy of the Company Exhibit 19.1 LIPELLA PHARMACEUTICALS INC. Insider Trading Policy For Employees, Officers and Directors 1. Introduction, Scope and Purpose of Policy In an effort to protect against prohibited “insider trading” by Lipella Pharmaceuticals Inc. (the “Company”) personnel, the Company’s Board of Directors has adopted this insider trading policy (this “Policy”) applicable to directors, officers, employee |
|
| February 7, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Gruber Michele - SC 13G/A Passive Investment SC 13G/A 1 g084014sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 6, 2024 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 (412) 894-1853 February 6, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington D.C. 20549 RE: Lipella Pharmaceuticals Inc. File No. 333-276815 Registration Statement on Form S-3 Ladies and Gentlemen: In accord |
|
| February 1, 2024 |
Form of Indenture for Senior Debt Securities. Exhibit 4.4 LIPELLA PHARMACEUTICALS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 2 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certi |
|
| February 1, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lipella Pharmaceuticals Inc. |
|
| February 1, 2024 |
Form of Indenture for Subordinated Debt Securities. Exhibit 4.5 LIPELLA PHARMACEUTICALS INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s |
|
| February 1, 2024 |
As filed with the Securities and Exchange Commission on February 1, 2024 As filed with the Securities and Exchange Commission on February 1, 2024 Registration No. |
|
| January 25, 2024 |
LIPO / Lipella Pharmaceuticals Inc. / Huang Leaf - SC 13G/A Passive Investment SC 13G/A 1 g083979sch13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the a |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| November 28, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2023 (November 21, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of |
|
| November 22, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2023 (November 21, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lip |
|
| November 14, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266397 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus Dated December 19, 2022 1,759,957 SHARES OF COMMON STOCK This prospectus supplement amends and supplements the prospectus dated December 19, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of the Registration Statement on Form S-1, as amended (No. 333-266 |
|
| November 9, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-275245 PROSPECTUS LIPELLA PHARMACEUTICALS INC. Up to 2,730,264 Shares of Common Stock Issuable Upon Exercise of Certain Pre-Funded Common Stock Purchase Warrants, Common Stock Purchase Warrants and Placement Agent Warrants This prospectus relates to the offer and resale of up to an aggregate of 2,730,264 shares (the “Warrant Shares”), of common |
|
| November 6, 2023 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 Lipella Pharmaceuticals Inc. 7800 Susquehanna St. Suite 505 Pittsburgh, PA 15208 November 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington D.C. 20549 RE: Lipella Pharmaceuticals Inc. File No. 333-275245 Registration Statement on Form S-1 Ladies and Gentlemen: In accordance with Rule 461 under the Securitie |
|
| November 1, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 1, 2023 As filed with the U.S. Securities and Exchange Commission on November 1, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction of incorporation or organ |
|
| November 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals, Inc. |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| October 26, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR ssSOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| October 26, 2023 |
Exhibit 99.2 Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules Pittsburgh, PA October 25, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the closing of its previously announce |
|
| October 26, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023, between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con |
|
| October 26, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 26, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 26, 2023 |
Exhibit 99.1 Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules Pittsburgh, PA October 24, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the entry, on October 23, 2023, into definitive a |
|
| October 26, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October 23, 2023, by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Secu |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Co |
|
| September 11, 2023 |
Exhibit 99.1 A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO lipellapharmaceuticals.com A Clinical Stage Biotechnology Company Addressing Serious Diseases with Significant Unmet Need NASDAQ:LIPO Disclaimers Theinformation inthispresentation isbeing provided soyoucanfamiliarize yourself with LipellaPharmaceuticals Inc.(“Lipella,”the“Company |
|
| August 14, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266397 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus Dated December 19, 2022 1,759,957 SHARES OF COMMON STOCK This prospectus supplement amends and supplements the prospectus dated December 19, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of the Registration Statement on Form S-1, as amended (No. 333-266 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 (August 4, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| August 8, 2023 |
Exhibit 10.1 AMMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1, dated August 4, 2023 (the “Amendment”), to the Employment Agreement entered into as of July 17, 2020 by and between Jonathan Kaufman and Lipella Pharmaceuticals Inc., a Delaware corporation (the “Employment Agreement”). The parties hereto hereby agree as follows: 1. Section 4.1 of the Employment Agreement is hereby deleted |
|
| August 8, 2023 |
Exhibit 10.2 AMMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1, dated August 4, 2023 (the “Amendment”), to the Employment Agreement entered into as of July 17, 2020 by and between Michael Chancellor and Lipella Pharmaceuticals Inc., a Delaware corporation (the “Employment Agreement”). The parties hereto hereby agree as follows: 1. Section 4.1 of the Employment Agreement is hereby delet |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 (July 27, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorp |
|
| August 2, 2023 |
Exhibit 10.1 LEASE AGREEMENT PART I - BASIC LEASE INFORMATION This Lease Agreement (“Lease”) is made and executed this 26th day of July, 2023, by and between Bridgeway Development Corporation (“Landlord”) and Lipella Pharmaceuticals Inc. (“Tenant”). This Lease consists of the following two parts: Part I which sets forth terms defined in this Lease (and certain obligations under the Lease) and whic |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 (June 17, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorpo |
|
| June 21, 2023 |
LIPO / Lipella Pharmaceuticals Inc / Chancellor Michael B - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| June 21, 2023 |
LIPO / Lipella Pharmaceuticals Inc / Kaufman Jonathan H - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| June 6, 2023 |
Lipella Pharmaceuticals Inc. 2020 Stock Incentive Plan, as amended and restated Exhibit 4.3 LIPELLA PHARMACEUTICALS INC. AMENDED AND RESTATED 2020 STOCK INCENTIVE PLAN 1. PURPOSE The purpose of this Amended and Restated 2020 Stock Incentive Plan (the “Plan”) is to encourage key employees, directors, and consultants of Lipella Pharmaceuticals Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by providing favorable oppor |
|
| June 6, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 6, 2023 As filed with the U.S. Securities and Exchange Commission on June 6, 2023 Registration No. 333-272387 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other jurisdi |
|
| June 2, 2023 |
As filed with Securities and Exchange Commission on June 2, 2023 As filed with Securities and Exchange Commission on June 2, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other jurisdiction of (I.R.S. Employer incorporation or organi |
|
| June 2, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Lipella Pharmaceuticals Inc. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 (May 30, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorpora |
|
| May 15, 2023 |
Exhibit 99.1 Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update Successful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaking presentation of Phase 2a study results at the American Urological Association Annual Meeting M |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Commissi |
|
| May 12, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266397 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus Dated December 19, 2022 1,759,957 SHARES OF COMMON STOCK This prospectus supplement amends and supplements the prospectus dated December 19, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of the Registration Statement on Form S-1, as amended (No. 333-266 |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella |
|
| April 3, 2023 |
Exhibit 99.1 Lipella Provides Business Update and Reports 2022 Financial Results Company Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights ● Appointed Douglas Johnston as CFO in November 2022 ● Successfully completed Initial Public Offering, attained NASDAQ CM listing ● Year-end cash balance in excess of $5 million Subsequent Events ● Attended Biotech Showcase a |
|
| April 3, 2023 |
As filed with the U.S. Securities and Exchange Commission on April 3, 2023 As filed with the U.S. Securities and Exchange Commission on April 3, 2023 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other j |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 (March 31, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorp |
|
| April 3, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-266397 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus Dated December 19, 2022 1,759,957 SHARES OF COMMON STOCK This prospectus supplement amends and supplements the prospectus dated December 19, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of the Registration Statement on Form S-1, as amended (No. 333-266 |
|
| March 31, 2023 |
Exhibit 3.1(i)(a) State of Delaware Secretary of State Division of Corporations Delivered 01:25 PM 12/19/2022 FILED 01:25 PM 12/19/2022 SR 20224308880 - File Number 3925021 SECOND AMENDED AND RESTATED CERTIFICATE INCORPORATION OF LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certif |
|
| March 31, 2023 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Lipella Pharmaceuticals Inc. (the “Company,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share (our “Common Stock”). G |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41575 Lipella Pharmaceuticals Inc. |
|
| March 31, 2023 |
Exhibit 3.1(i)(c) |
|
| March 31, 2023 |
Exhibit 3.1(ii) SECOND AMENDED AND RESTATED BY-LAWS OF Lipella Pharmaceuticals Inc. (the “Corporation”) Article I Offices Section 1.01. Registered Office. The registered office of the Corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 1.02. Other Offices. The Corporation shall also have and maintain an office or principal place of business at suc |
|
| March 31, 2023 |
Exhibit 3.1(i)(b) |
|
| March 29, 2023 |
LIPO / Lipella Pharmaceuticals Inc / Gruber Michele - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) March 19, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 (March 21, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incor |
|
| February 9, 2023 |
LIPO / Lipella Pharmaceuticals Inc / Huang Leaf - SC 13G Passive Investment SC 13G 1 g08339013g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lipella Pharmaceuticals Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 2, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 (January 11, 2023) Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of |
|
| February 2, 2023 |
Exhibit 99.1 Biotech Showcase 2023 San Francisco, CA January 11, 2003 Liposomal Drug Delivery to Mucosal Surfaces1 Disclaimers The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, “Lipella” the “Company,” “we,” “us,” or “our”) during this informational meeting. We request that you keep any informat |
|
| January 12, 2023 |
Exhibit 99.2 Liposomal Drug Delivery to Mucosal Surfaces Biotech Showcase 2023TM January 11, 2023 Wednesday, 2:00 PM ET Track: Yosemite A (Ballroom Level) (Nasdaq: LIPO) 1 2 Disclaimers Forward-Looking Statements The information in this presentation is being provided so you can familiarize yourself with Lipella Pharmaceuticals Inc. (together with its subsidiaries, “Lipella” the “Company,” “we,” “u |
|
| January 12, 2023 |
Exhibit 99.1 Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 Results to be Presented at BIOTECH SHOWCASETM 2023 on Wednesday, January 11th at 2:00pm PST Pittsburgh, PA - January 11, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company focused on developing new drugs by |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 005-93847 20-2388040 (State or other jurisdiction of incorporation) (Comm |
|
| December 29, 2022 |
LIPO / Lipella Pharmaceuticals Inc / Chancellor Michael B - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway – 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| December 29, 2022 |
LIPO / Lipella Pharmaceuticals Inc / Kaufman Jonathan H - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* LIPELLA PHARMACEUTICALS INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53630L100 (CUSIP Number) David E. Danovitch, Esq. Sullivan & Worcester LLP 1633 Broadway ? 32nd Floor New York, NY 10019 (212) 660-3000 |
|
| December 21, 2022 |
424B4 1 g083316424b4.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-266397 PROSPECTUS 1,217,391 SHARES OF COMMON STOCK This is the initial public offering by Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”, “we”, “us” or “our”). We have registered on the registration statement of which this prospectus forms a part a total of 2,926,624 shares of our co |
|
| December 21, 2022 |
424B4 1 g083317424b4.htm 424B4 Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-266397 PROSPECTUS 1,759,957 SHARES OF COMMON STOCK This prospectus relates to the resale by the selling stockholders identified herein (the “Selling Stockholders”) of an aggregate of 1,759,957 shares of common stock, par value $0.0001 per share (“Common Stock”) issued by Lipella Pharmaceuticals Inc., a D |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 LIPELLA PHARMACEUTICALS INC. |
|
| December 16, 2022 |
CORRESP 1 filename1.htm VIA EDGAR December 16, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attn: Jason Drory Re: LIPELLA PHARMACEUTICALS INC. File No. 333-266397 Registration Statement on Form S-1, as amended Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange C |
|
| December 15, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 CORRESP 1 filename1.htm Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 December 15, 2022 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Lipella Pharmaceuticals Inc. File No. 333-266397 Registration Statement on Form S-1, as amended Dear Sir and Madam: |
|
| December 15, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 15, 2022 As filed with the U.S. Securities and Exchange Commission on December 15, 2022 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction |
|
| December 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| December 13, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 13, 2022 As filed with the U.S. Securities and Exchange Commission on December 13, 2022 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction |
|
| December 13, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| December 13, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 CORRESP 1 filename1.htm Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 December 13, 2022 Via EDGAR Jason Drory Anne Parker Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed December |
|
| December 13, 2022 |
Form of Underwriting Agreement EX-1.1 2 g083294ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 LIPELLA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT [●], 2022 Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, LIPELLA PHARMACEUTICALS INC., a Delaware corporation (collectively with its affiliates, including, without li |
|
| December 8, 2022 |
Form of Underwriting Agreement EX-1.1 2 g083286ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 LIPELLA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT [●], 2022 Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, LIPELLA PHARMACEUTICALS INC., a Delaware corporation (collectively with its affiliates, including, without li |
|
| December 8, 2022 |
Exhibit 4.1 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, |
|
| December 8, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 December 8, 2022 Via EDGAR Jason Drory Anne Parker Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed November 28, 2022 File No. 333-26 |
|
| December 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| December 8, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 8, 2022 As filed with the U.S. Securities and Exchange Commission on December 8, 2022 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction |
|
| November 28, 2022 |
Form of Indemnification Agreement for Lipella Pharmaceuticals Inc. Exhibit 10.15 LIPELLA PHARMACEUTICALS INC. FORM OF INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of [●] (the “Effective Date”), by and between Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), and [●] (the “Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors |
|
| November 28, 2022 |
Form of Lipella Pharmaceuticals Inc. 2020 Stock Incentive Plan, as amended and restated. Exhibit 10.8 LIPELLA PHARMACEUTICALS INC. AMENDED AND RESTATED 2020 STOCK INCENTIVE PLAN 1. PURPOSE The purpose of this Amended and Restated 2020 Stock Incentive Plan (the ?Plan?) is to encourage key employees, directors, and consultants of Lipella Pharmaceuticals Inc. (the ?Company?) and its Subsidiaries (as defined below) to continue their association with the Company by providing favorable oppo |
|
| November 28, 2022 |
Exhibit 10.19 February 9, 2022 Jonathan Kaufman PhD CEO Lipella Pharmaceuticals Inc. 7800 Susquehanna St, Suite 505 Pittsburgh, PA 15208 Dear Jonathan, This letter agreement (this ?Agreement?) will confirm the understanding and agreement between Young & Partners LLC (?Young & Partners?) and Lipella Pharmaceuticals Inc. (the ?Company?) as follows: 1. The Company hereby engages Young & Partners to p |
|
| November 28, 2022 |
Amended and Restated By-laws, as currently in effect EX-3.1IIA 5 g083258ex3-1iia.htm EXHIBIT 3.1IIA Exhibit 3.1(ii)(a) AMENDED AND RESTATED BY-LAWS OF LIPELLA PHARMACEUTICALS INC. ADOPTED FEBRUARY 6, 2010 AMENDED AND RESTATED BY-LAWS OF LIPELLA PHARMACEUTICALS INC. TABLE OF CONTENTS Page ARTICLE 1 MEETINGS OF STOCKHOLDERS 1 Section 1.1 Place of Meetings 1 Section 1.2 Annual Meetings 1 Section 1.3 Special Meetings 1 Section 1.4 Notice of Meetings 1 S |
|
| November 28, 2022 |
EX-FILING FEES 26 g083258ex107.htm EXHIBIT 107 Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee N |
|
| November 28, 2022 |
EX-3.1IB 3 g083258ex3-1ib.htm EXHIBIT 3.1IB Exhibit 3.1(i)(b) SECOND AMENDED AND RESTATED CERTIFICATE INCORPORATION OF LIPELLA PHARMACEUTICALS INC. Lipella Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: ONE: The name of the Corporation is Lipella Pharmaceuticals Inc., which was the name under whic |
|
| November 28, 2022 |
Exhibit 10.9 LIPELLA PHARMACEUTICALS INC. Amended and Restated 2020 Stock Incentive Plan Stock Option Agreement This Stock Option Agreement and the associated grant award information (the ?Customizing Information?), which Customizing Information is provided in written form as the Stock Option Schedule or is available in electronic form from the recordkeeper for the Lipella Pharmaceuticals Inc. Ame |
|
| November 28, 2022 |
Exhibit 10.18 PROMISSORY NOTE $250,000.00 November 1, 2022 FOR VALUE RECEIVED, the undersigned, Lipella Pharmaceuticals Inc. (the ?Borrower?), promises to pay to the order of Jonathan Kaufman (the ?Lender?), the principal sum of Two Hundred Fifty Thousand Dollars and Zero Cents ($250,000.00), with interest thereon at the rate of eight and three quarters percent (8.75%) per annum, said principal an |
|
| November 28, 2022 |
Lease dated June 1, 2019 between Bridgeway Development Corporation and Lipella Pharmaceuticals Inc. Exhibit 10.11 LEASE AGREEMENT PART I - BASIC LEASE INFORMATION This Lease Agreement (?Lease?) is made and executed this 1st day of June, 2019, by and between Bridgeway Development Corporation (?Landlord?) and Lipella Pharmaceuticals Inc. (?Tenant?). This Lease consists of the following two parts: Part I which sets forth terms defined in this Lease (and certain obligations under the Lease) and whic |
|
| November 28, 2022 |
EX-10.3 8 g083258ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(iv) BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into on November 9, 20 |
|
| November 28, 2022 |
Exhibit 3.1(ii)(b) SECOND AMENDED AND RESTATED BY-LAWS OF LIPELLA PHARMACEUTICALS INC. (the ?Corporation?) Article I Offices Section 1.01. Registered Office. The registered office of the Corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 1.02. Other Offices. The Corporation shall also have and maintain an office or principal place of business at |
|
| November 28, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 28, 2022 As filed with the U.S. Securities and Exchange Commission on November 28, 2022 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction |
|
| November 28, 2022 |
Amended and Restated Certificate of Incorporation, as currently in effect EX-3.1IA 2 g083258ex3-1ia.htm EXHIBIT 3.1IA Exhibit 3.1(i)(a) Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “LIPELLA PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE TWELFTH DAY OF SEPTEMBER, A.D. 2008, AT 11:03 O’CLOCK A.M. /s/Jeffrey W. Bullock Jeffrey |
|
| November 28, 2022 |
Form of Stock Option Agreement for Lipella Pharmaceuticals Inc. 2008 Stock Incentive Plan EX-10.5 10 g083258ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 LIPELLA PHARMACEUTICALS INC. 2008 INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Optionee: The Optionee has been granted an Option to purchase a number of shares of Lipella Pharmaceuticals Inc. Common Stock, $.0001 par value per share, as designated below (the “Shares”), subject to the terms and conditions of the Lipella Ph |
|
| November 28, 2022 |
EX-10.16 21 g083258ex10-16.htm EXHIBIT 10.16 Exhibit 10.16 PROMISSORY NOTE $25,000.00 August 21, 2009 FOR VALUE RECEIVED, the undersigned, Lipella Pharmaceuticals Inc. (the “Borrower”), promises to pay to the order of Michael Chancellor (the “Lender”), the principal sum of Twenty-Five Thousand Dollars and Zero Cents ($25,000.00), with interest thereon at the rate of eight and three quarters percen |
|
| November 28, 2022 |
Exhibit 10.12 SECOND AMENDMENT TO LEASE AGREEMENT This Lease Agreement (?Lease?) is made and executed this 7th day of July, 2020, by and between Bridgeway Development Corporation (?Landlord?) and Lipella Pharmaceuticals Inc. (?Tenant?). WHERE AS, the Landlord and Tenant executed a lease dated June 1, 2019 (the ?Lease?); WHERE AS, Landlord and Tenant executed an amended lease on June 30, 2020 (?Fir |
|
| November 28, 2022 |
Exhibit 10.14 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(iv) BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LIPELLA PHARMACEUTICALS INC. NOTE CANCELLATION AND STOCK PURCHASE AGREEMENT THIS NOTE CANCELLATION AND STOCK PURCHASE AGREEMENT (the ?Agreement?) i |
|
| November 28, 2022 |
EX-10.13 18 g083258ex10-13.htm EXHIBIT 10.13 Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10)(iv) BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Execution Copy SHAREHOLDERS AGREEMENT This Shareholders Agreement (this “Agreement”) is made as of May |
|
| November 28, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 CORRESP 1 filename1.htm Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, Pennsylvania 15208 November 28, 2022 Via EDGAR Jason Drory Anne Parker Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October |
|
| November 28, 2022 |
EX-10.17 22 g083258ex10-17.htm EXHIBIT 10.17 Exhibit 10.17 PROMISSORY NOTE $50,000.00 January 25, 2015 FOR VALUE RECEIVED, the undersigned, Lipella Pharmaceuticals Inc. (the “Borrower”), promises to pay to the order of Michael Chancellor (the “Lender”), the principal sum of Fifty Thousand Dollars and Zero Cents ($50,000.00), with interest thereon at the rate of eight and three quarters percent (8. |
|
| November 28, 2022 |
Exhibit 3.1(i)(c) LIPELLA PHARMACEUTICALS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK Pursuant to Sections 103 and 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Lipella Pharmaceuticals Inc., a corporation organized and existing under the DGCL (the “Corporation”), does hereby submit the following: WHEREAS, the Amende |
|
| November 28, 2022 |
Exhibit 10.10 LIPELLA PHARMACEUTICALS INC. Amended and Restated 2020 Stock Incentive Plan Restricted Stock Unit Agreement This Restricted Stock Unit Agreement and the associated grant award information (the “Customizing Information”), which Customizing Information is provided in written form as the Restricted Stock Unit Schedule or is available in electronic form from the recordkeeper for the Lipe |
|
| November 28, 2022 |
Exhibit 10.7 LIPELLA PHARMACEUTICALS INC. 2020 INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Optionee: The Optionee has been granted an Option to purchase a number of shares of Lipella Pharmaceuticals Inc. Common Stock, $.0001 par value per share, as designated below (the ?Shares?), subject to the terms and conditions of the Lipella Pharmaceuticals Inc. 2020 Stock Incentive Pl |
|
| November 28, 2022 |
Lipella Pharmaceuticals Inc. 2020 Stock Incentive Plan. Exhibit 10.6 LIPELLA PHARMACEUTICALS INC. 2020 STOCK INCENTIVE PLAN Effective July 6, 2020 ARTICLE I PURPOSE AND ADOPTION OF THE PLAN 1.1 Purpose. The purpose of the Lipella Pharmaceuticals Inc. 2020 Stock Incentive Plan (as amended from time to time, the ?Plan?) is to assist the Company in attracting and retaining highly competent employees, officers, directors, consultants and advisors, to act a |
|
| November 28, 2022 |
Lipella Pharmaceuticals Inc. 2008 Stock Incentive Plan EX-10.4 9 g083258ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 LIPELLA PHARMACEUTICALS INC. 2008 STOCK INCENTIVE PLAN Effective March , 2008 Article I PURPOSE AND ADOPTION OF THE PLAN 1.1 Purpose. The purpose of the Lipella Pharmaceuticals Inc. 2008 Stock Incentive Plan (as amended from time to time, the “Plan”) is to assist the Company in attracting and retaining highly competent employees, officers, dire |
|
| October 31, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 CORRESP 1 filename1.htm Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 October 31, 2022 Via EDGAR Jason Drory Eric Atallah U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October 24, 202 |
|
| October 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| October 24, 2022 |
As filed with the U.S. Securities and Exchange Commission on October 24, 2022 As filed with the U.S. Securities and Exchange Commission on October 24, 2022 Registration No. 333-266397 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction |
|
| October 24, 2022 |
Form of Underwriting Agreement Exhibit 1.1 LIPELLA PHARMACEUTICALS INC. UNDERWRITING AGREEMENT [?], 2022 Spartan Capital Securities, LLC 45 Broadway, 19th Floor New York, NY 10006 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, LIPELLA PHARMACEUTICALS INC., a Delaware corporation (collectively with its affiliates, including, without limitation, all entities disclosed or de |
|
| October 24, 2022 |
Exhibit 4.2 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT, OR ANY OF THE UNDERLYING SECURITIES, |
|
| October 21, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 October 24, 2022 Via EDGAR Jason Drory Anne Parker U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Lipella Pharmaceuticals Inc. Registration Statement on Form S-1 Filed July 29, 2022 File No. 333-266397 Dear Sir and Madam: This |
|
| July 29, 2022 |
EX-10.2 3 g083080ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K PROMULGATED UNDER THE SECURITIES ACT OF 1933 BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreemen |
|
| July 29, 2022 |
Employment Agreement by and between the Company and Jonathan Kaufman, effective as of July 17, 2020 EX-10.1 2 g083080ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(b)(10)(iv) OF REGULATION S-K PROMULGATED UNDER THE SECURITIES ACT OF 1933 BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreemen |
|
| July 29, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| July 29, 2022 |
Letter Agreement, dated October 14, 2021, between the Company and Stonewall Finance, LLC EX-10.3 4 g083080ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 October 14, 2021 Lipella Pharmaceuticals Inc. Attn: Jonathan Kaufman, PhD 7800 Susquenhanna St. Suite 5050 Pittsburgh, PA 15208 Re: Accounting and CFO Services This letter confirms the Accounting and CFO Services LIPELLA PHARMACEUTICALS INC. has asked STONEWALL FINANCE, LLC to perform, and under the terms, which we have agreed to do that work. |
|
| July 29, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 July 29, 2022 Via EDGAR Jason Drory Anne Parker U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted April 20, 2022 CIK No. 0001347242 |
|
| July 29, 2022 |
Power of Attorney (included on signature page) As filed with the U.S. Securities and Exchange Commission on July 29, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPELLA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-2388040 (State or other jurisdiction of incorporation or organiza |
|
| April 20, 2022 |
DRSLTR 1 filename1.htm April 20, 2022 CONFIDENTIAL SUBMISSION VIA EDGAR Draft Registration Statement U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Lipella Pharmaceuticals Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of our client, Lipella Pharmaceuticals Inc. (the “Company”), |
|
| April 20, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| April 20, 2022 |
As submitted confidentially to the U.S. Securities and Exchange Commission on April 20, 2022, pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi |
|
| April 20, 2022 |
Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 DRSLTR 1 filename1.htm Lipella Pharmaceuticals Inc. 7800 Susquehanna St., Suite 505 Pittsburgh, PA 15208 April 20, 2022 Via EDGAR Jason Drory Anne Parker U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Lipella Pharmaceuticals Inc. Draft Registration Statement on Form S-1 Submitted February 14, 2022 CIK No. 00 |
|
| April 20, 2022 |
Exhibit 10.3 October 14, 2021 Lipella Pharmaceuticals Inc. Attn: Jonathan Kaufman, PhD 7800 Susquenhanna St. Suite 5050 Pittsburgh, PA 15208 Re: Accounting and CFO Services This letter confirms the Accounting and CFO Services LIPELLA PHARMACEUTICALS INC. has asked STONEWALL FINANCE, LLC to perform, and under the terms, which we have agreed to do that work. The intention of this letter is to confir |
|
| April 20, 2022 |
EX-10.2 3 filename3.htm Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(b)(10)(iv) BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into as of July 17, 2020 (the “Effective |
|
| April 20, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PURSUANT TO ITEM 601(b)(10)(iv) BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into as of July 17, 2020 (the “Effective Date”), by and between |
|
| February 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lipella Pharmaceuticals Inc. |
|
| February 14, 2022 |
DRS 1 filename1.htm As submitted confidentially to the U.S. Securities and Exchange Commission on February 14, 2022, pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EX |
